From a difficult Phase 2 to FDA approval: how Regeneron rebuilt its garetosmab FOP programme
FDA approval gives adults with fibrodysplasia ossificans progressiva another treatment option after OPTIMA recorded just one to two new bone lesions with Pasatru versus 19 with placebo over 56 weeks.